326 related articles for article (PubMed ID: 38077327)
41. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
42. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy.
Guo R; Li J; Hu J; Fu Q; Yan Y; Xu S; Wang X; Jiao F
Int Immunopharmacol; 2023 Jul; 120():110417. PubMed ID: 37276826
[TBL] [Abstract][Full Text] [Related]
43. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.
Yu L; Sun M; Zhang Q; Zhou Q; Wang Y
Front Immunol; 2022; 13():982026. PubMed ID: 36159789
[TBL] [Abstract][Full Text] [Related]
44. Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
[TBL] [Abstract][Full Text] [Related]
45. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
46. Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response.
McGoverne I; Dunn J; Batham J; Tu WJ; Chrisp J; Rao S
BMC Immunol; 2020 Apr; 21(1):22. PubMed ID: 32316916
[TBL] [Abstract][Full Text] [Related]
47. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
48. Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects.
Banday AH; Abdalla M
Curr Med Chem; 2023; 30(28):3215-3237. PubMed ID: 35986535
[TBL] [Abstract][Full Text] [Related]
49. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
50. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
51. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
52. TIM-3, a promising target for cancer immunotherapy.
He Y; Cao J; Zhao C; Li X; Zhou C; Hirsch FR
Onco Targets Ther; 2018; 11():7005-7009. PubMed ID: 30410357
[TBL] [Abstract][Full Text] [Related]
53. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
[TBL] [Abstract][Full Text] [Related]
54. A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.
Liu Z; Ren Y; Weng S; Xu H; Li L; Han X
Front Immunol; 2022; 13():809761. PubMed ID: 35140720
[TBL] [Abstract][Full Text] [Related]
55. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
56. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.
Barsheshet Y; Voloshin T; Brant B; Cohen G; Koren L; Blatt R; Cahal S; Haj Khalil T; Zemer Tov E; Paz R; Klein-Goldberg A; Tempel-Brami C; Jacobovitch S; Volodin A; Kan T; Koltun B; David C; Haber A; Giladi M; Weinberg U; Palti Y
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430552
[TBL] [Abstract][Full Text] [Related]
57. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
[TBL] [Abstract][Full Text] [Related]
58. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
[TBL] [Abstract][Full Text] [Related]
59. The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
[TBL] [Abstract][Full Text] [Related]
60. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Li X; Wang R; Fan P; Yao X; Qin L; Peng Y; Ma M; Asley N; Chang X; Feng Y; Hu Y; Zhang Y; Li C; Fanning G; Jones S; Verrill C; Maldonado-Perez D; Sopp P; Waugh C; Taylor S; Mcgowan S; Cerundolo V; Conlon C; McMichael A; Lu S; Wang X; Li N; Dong T
Front Oncol; 2019; 9():1066. PubMed ID: 31709176
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
